HCPLive Podcasts
by HCPLive.com
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇨🇱CL · Medicine#149500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
150 to 900🎙 Daily cadence·234 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇨🇱100% - Active Followers
Loyal subscribers who consistently listen
150 to 900
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 24 epsHosts
Recent guests
Recent episodes
2: Joint Ventures Recaps Influential EULAR Studies in SLE, RA, and More
Jul 16, 2026
42m 02s
1: Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
Jul 9, 2026
42m 58s
Liver Lineup: HDV Diagnosis, Bulevirtide, and the Delta Pipeline
Jul 9, 2026
44m 44s
Joint Ventures: Lupus Health Inequalities, Growing Burden of ICI-Arthritis at EULAR 2026
Jun 26, 2026
13m 26s
Joint Ventures: CAR-T, Early Diagnosis Reshape Scleroderma at EULAR 2026
Jun 24, 2026
13m 18s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/16/26 | rheumatologyEULAR studies+4 | — | AB-101 Allogeneic NK Cell TherapyCARLYSLE: Obe-Cel CAR T+6 | — | EULAR 2026rheumatology+6 | — | 42m 02s | ||
| 7/9/26 | hepatitis Bfunctional cure+4 | Tatyana Kushner, MD | bepirovirsenNew England Journal of Medicine+1 | — | hepatitis Bbepirovirsen+5 | — | 42m 58s | ||
| 7/9/26 | hepatitis delta virusHDV diagnosis+5 | Tatyana Kushner, MD | bulevirtideLivdelzi+3 | United States | hepatitis delta virusHDV diagnosis+5 | — | 44m 44s | ||
| 6/26/26 | lupushealth inequalities+4 | Sarah Dyball, MBBS, PhDKate Harnden, MBChB | Freeman HospitalCentre for Musculoskeletal Research+3 | London | lupushealth inequalities+4 | — | 13m 26s | ||
| 6/24/26 | sclerodermaCAR-T therapy+4 | Vishal Kakkar | University of LeedsEuropean Alliance of Associations for Rheumatology | — | sclerodermaCAR-T+5 | — | 13m 18s | ||
| 6/24/26 | rheumatologyrheumatoid arthritis+5 | Laurence Duquenne, MD | methotrexatebiologic+2 | — | rheumatoid arthritisEULAR 2026+5 | — | 7m 30s | ||
| 5/29/26 | RheumatologyEULAR Congress Preview+4 | — | — | London | EULAR 2026Rheumatology+5 | — | 42m 37s | ||
| 5/28/26 | B cell therapiesrheumatic disease+4 | Lucy Carter, MBBS, PhD | ianalumabrituximab+3 | — | B cell depletionianalumab+6 | — | 36m 07s | ||
| 5/28/26 | B cell-targeted therapyrheumatic disease+5 | Lucy Carter, MBBS, PhD | rituximabobinutuzumab+4 | — | B cell therapyrheumatology+6 | — | 29m 38s | ||
| 5/28/26 | GLP-1 receptor agonistsrheumatoid arthritis+4 | — | GLP-1 receptor agonistsUniversity of Leeds+1 | Newcastle | GLP-1 receptor agonistsrheumatoid arthritis+5 | — | 27m 54s | ||
| 5/28/26 | GLP-1 receptor agonistsrheumatological disease+5 | — | GLP-1 receptor agonistsexenatide+3 | — | GLP-1 receptor agonistsrheumatology+7 | — | 28m 45s | ||
| 5/28/26 | therapeutic strategiessystemic lupus erythematosus+4 | — | nipocalimabdeucravacitinib+2 | — | nipocalimabdeucravacitinib+4 | — | 25m 00s | ||
| 5/28/26 | rheumatologic diseasepatient-centered care+4 | — | RheumatologyLiveLeeds Institute of Rheumatic and Musculoskeletal Medicine+2 | — | rheumatologyclinical trials+4 | — | 22m 39s | ||
| 5/6/26 | IBD therapiespatient outcomes+4 | David Rubin, MD | Crohn's diseaseulcerative colitis+2 | — | IBDtherapies+5 | — | 11m 00s | ||
| 4/19/26 | FSGSdrug development+2 | — | SparsentanFSGS | — | FSGSSparsentan+2 | — | 13m 47s | ||
| 4/16/26 | liver healthwomen's health+5 | Meena Bansal Md | FIB-4GLP-1s+2 | — | liver diseasefibrosis risk+5 | — | 44m 51s | ||
| 4/7/26 | genetic testingcholestatic liver disease+4 | Saul Karpen Md PhdRobert Gish Md | Liver Lineup | — | genetic panelscholestasis+6 | — | 56m 11s | ||
| 3/15/26 | healthcareclinical updates+3 | — | RAINIERlorundrostat+5 | — | povetaciceptlorundrostat+3 | — | 4m 58s | ||
| 2/24/26 | healthcareclinical updates+1 | — | COMP360Obinutuzumab+4 | — | healthcare storiesclinical updates+1 | — | 5m 49s | ||
| 2/18/26 | ICD-10short bowel syndrome+3 | Alan Buchman Md Msph | the Intestinal Rehabilitation and Transplant Centerthe University of Illinois at Chicago+2 | US | ICD-10-CM codesWorld Health Organization+3 | — | 7m 07s | ||
| 2/13/26 | platelet incrementshematology+1 | Ruchika Goel Md | — | MD | plateletsincrements+1 | — | 7m 13s | ||
| 2/9/26 | healthcareFDA+3 | — | DibutepinephrineRoflumilast Cream+5 | — | healthcare storiesrecap+1 | — | 5m 06s | ||
| 2/4/26 | metabolic dysfunction–associated steatotic liver diseasemetabolic dysfunction–associated steatohepatitis+6 | — | semaglutideFGF-21+2 | — | MASLDMASH+6 | — | 29m 08s | ||
| 2/4/26 | viral hepatitishepatitis C+5 | — | statinsGLP-1 agonists+2 | — | curative therapiesscreening barriers+4 | — | 28m 52s |
Showing 24 of 24
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for HCPLive Podcasts
Peaked at #149 in CL, currently #149 in CL.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| CL | — | #149 | #149 | — |
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.